You are here: Industry Insights > HBV

News List

Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 pharmafocusasia
November 28, 2018
Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment .......
China's NMPA approves Gilead's Vemlidy for HBV biospectrumasia
November 20, 2018
HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy accounting
China's NMPA approves Gilead's Vemlidy for HBV biospectrum
November 20, 2018
HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy – accounting for almost one-third of all patients currently requiring therapy worldwide.
Hepatitis B Drug Market to Reach RMB 20 Billion in China by 2020 Daling
November 01, 2018
A Brief Description of Anti-Hepatitis B Drugs
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Sensitive new assay detects hepatitis B infection in single liver cells and serum europeanpharmaceuticalreview
April 16, 2018
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients…

Previous page 1 2 3 Next page